ES2655820T3 - Formulación que comprende un profármaco de gemcitabina - Google Patents

Formulación que comprende un profármaco de gemcitabina Download PDF

Info

Publication number
ES2655820T3
ES2655820T3 ES15733498.8T ES15733498T ES2655820T3 ES 2655820 T3 ES2655820 T3 ES 2655820T3 ES 15733498 T ES15733498 T ES 15733498T ES 2655820 T3 ES2655820 T3 ES 2655820T3
Authority
ES
Spain
Prior art keywords
formulation
dma
volume
phosphate
gemcitabine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15733498.8T
Other languages
English (en)
Spanish (es)
Inventor
Hugh GRIFFITH
Gordon KENNOVIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nucana PLC
Original Assignee
Nucana PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1411253.6A external-priority patent/GB201411253D0/en
Priority claimed from GBGB1417646.5A external-priority patent/GB201417646D0/en
Application filed by Nucana PLC filed Critical Nucana PLC
Application granted granted Critical
Publication of ES2655820T3 publication Critical patent/ES2655820T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES15733498.8T 2014-06-25 2015-06-25 Formulación que comprende un profármaco de gemcitabina Active ES2655820T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB201411253 2014-06-25
GBGB1411253.6A GB201411253D0 (en) 2014-06-25 2014-06-25 Prodrug
IN2050MU2014 2014-06-25
IN2050MU2014 2014-06-25
GB201417646 2014-10-06
GBGB1417646.5A GB201417646D0 (en) 2014-10-06 2014-10-06 Formulations of phosphate derivatives
PCT/GB2015/051858 WO2015198059A1 (en) 2014-06-25 2015-06-25 Formulation comprising a gemcitabine-prodrug

Publications (1)

Publication Number Publication Date
ES2655820T3 true ES2655820T3 (es) 2018-02-21

Family

ID=53499028

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15733498.8T Active ES2655820T3 (es) 2014-06-25 2015-06-25 Formulación que comprende un profármaco de gemcitabina

Country Status (30)

Country Link
US (4) US10117888B2 (enExample)
EP (2) EP3119794B1 (enExample)
JP (3) JP6855248B2 (enExample)
KR (2) KR20220104270A (enExample)
CN (2) CN110882268A (enExample)
AU (2) AU2015278900B2 (enExample)
BR (1) BR112016025787B1 (enExample)
CA (1) CA2944966C (enExample)
CL (1) CL2016003261A1 (enExample)
CY (1) CY1119772T1 (enExample)
DK (1) DK3119794T3 (enExample)
EA (1) EA033046B1 (enExample)
ES (1) ES2655820T3 (enExample)
HK (1) HK1244437A1 (enExample)
HR (1) HRP20180007T1 (enExample)
HU (1) HUE036011T2 (enExample)
IL (2) IL248345B (enExample)
LT (1) LT3119794T (enExample)
MX (2) MX373942B (enExample)
MY (1) MY186584A (enExample)
NO (1) NO3119794T3 (enExample)
PH (1) PH12016502552A1 (enExample)
PL (1) PL3119794T3 (enExample)
PT (1) PT3119794T (enExample)
RS (1) RS56752B1 (enExample)
SG (1) SG11201608809RA (enExample)
SI (1) SI3119794T1 (enExample)
SM (1) SMT201800041T1 (enExample)
TW (2) TWI674097B (enExample)
WO (1) WO2015198059A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
EP3447061B1 (en) 2011-03-01 2021-11-24 NuCana plc Pharmaceutical formulation comprising a phosphoramidate derivative of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
AU2013346515B2 (en) 2012-11-16 2017-05-25 NuCana plc Process for preparing nucleoside prodrugs
NO3119794T3 (enExample) 2014-06-25 2018-03-10
MY183198A (en) * 2014-06-25 2021-02-18 Nucana Biomed Ltd Gemcitabine prodrugs
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
EA031727B1 (ru) 2014-11-28 2019-02-28 НУКАНА ПиЭлСи Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
CN106478753A (zh) * 2015-09-16 2017-03-08 博瑞生物医药（苏州）股份有限公司 一种nuc‑1031单一异构体的制备方法和用途
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
MX385837B (es) 2015-10-05 2025-03-18 NuCana plc Terapia de combinacion.
KR20180101370A (ko) 2015-12-11 2018-09-12 뉴카나 피엘씨 인산염 유도체 및 젬시타빈 전구약물 nuc-1031의 부분입체 이성질체 선별적 합성
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
CN110035740B (zh) 2016-11-02 2023-08-04 中枢疗法公司 稳定的水性辣椒素可注射制剂及其医学用途
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
CA3069540A1 (en) 2017-07-20 2019-01-24 Centrexion Therapeutics Corporation Methods and compositions for treatment of pain using capsaicin
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
CN109956986B (zh) 2017-12-22 2021-04-27 浙江柏拉阿图医药科技有限公司 肝递送吉西他滨前体药物核苷环磷酸酯化合物及应用
WO2023076878A1 (en) * 2021-10-26 2023-05-04 Emphascience Inc. Ready-to-dilute formulation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
WO1999037753A1 (en) 1998-01-23 1999-07-29 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
CN1390227A (zh) 1999-07-22 2003-01-08 新生物生物公司 酶催化的治疗活化
CN1181829C (zh) * 2000-11-03 2004-12-29 中国人民解放军军事医学科学院附属医院 吉西他滨溶液制剂
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
CA2595606C (en) 2005-01-27 2014-12-16 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including ndga compounds
CA2635797C (en) * 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
EP1913962A1 (en) * 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
WO2011008985A2 (en) 2009-07-15 2011-01-20 Georgia Tech Research Corporation Methods and compositions for improved delivery of therapeutic and diagnostic agents
MX2012005677A (es) * 2009-11-20 2012-08-23 Clavis Pharma Asa Formulaciones parentales de derivados de gemcitabina.
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
KR101231925B1 (ko) * 2010-10-27 2013-02-08 씨제이제일제당 (주) 젬시타빈의 전구약물 및 이의 제조방법
US9107943B2 (en) * 2012-01-20 2015-08-18 Aratana Therapeutics Nv Eye drop composition
WO2014074725A1 (en) 2012-11-07 2014-05-15 Ohio State Innovation Foundation Substituted gemcitabine aryl amide analogs
AU2013346515B2 (en) 2012-11-16 2017-05-25 NuCana plc Process for preparing nucleoside prodrugs
KR20160099090A (ko) 2013-11-27 2016-08-19 아이데닉스 파마슈티칼스 엘엘씨 간암의 치료를 위한 뉴클레오티드
MY183198A (en) 2014-06-25 2021-02-18 Nucana Biomed Ltd Gemcitabine prodrugs
NO3119794T3 (enExample) 2014-06-25 2018-03-10
CN106795198B (zh) 2014-07-22 2019-09-06 努卡那公共有限公司 用于制备吉西他滨-[苯基(苄氧基-l-丙氨酸基)]磷酸酯的方法
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
TR201806642T4 (tr) 2015-05-14 2018-06-21 NuCana plc Kanser tedavileri.
MX385837B (es) 2015-10-05 2025-03-18 NuCana plc Terapia de combinacion.
KR20180101370A (ko) 2015-12-11 2018-09-12 뉴카나 피엘씨 인산염 유도체 및 젬시타빈 전구약물 nuc-1031의 부분입체 이성질체 선별적 합성
WO2017109486A1 (en) 2015-12-23 2017-06-29 Nucana Biomed Limited Combination therapy
AU2015418015B2 (en) 2015-12-23 2021-12-09 NuCana plc Combination therapy
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Also Published As

Publication number Publication date
CL2016003261A1 (es) 2017-10-06
JP2022031659A (ja) 2022-02-22
US11040051B2 (en) 2021-06-22
DK3119794T3 (en) 2018-01-22
KR102421929B1 (ko) 2022-07-15
IL248345B (en) 2020-10-29
IL276199A (en) 2020-09-30
LT3119794T (lt) 2018-02-12
TWI765176B (zh) 2022-05-21
AU2015278900B2 (en) 2019-04-04
MY186584A (en) 2021-07-28
SMT201800041T1 (it) 2018-03-08
RS56752B1 (sr) 2018-04-30
JP2017519022A (ja) 2017-07-13
US20190022118A1 (en) 2019-01-24
CA2944966A1 (en) 2015-12-30
MX2020004054A (es) 2021-11-30
BR112016025787A2 (pt) 2017-08-15
CN106470672A (zh) 2017-03-01
PH12016502552A1 (en) 2017-04-10
US20220031727A1 (en) 2022-02-03
MX2016015629A (es) 2017-08-02
WO2015198059A1 (en) 2015-12-30
SI3119794T1 (en) 2018-02-28
CY1119772T1 (el) 2018-06-27
US11707477B2 (en) 2023-07-25
MX388313B (es) 2025-03-19
AU2015278900A1 (en) 2016-10-27
JP6970221B2 (ja) 2021-11-24
JP6855248B2 (ja) 2021-04-07
HRP20180007T1 (hr) 2018-02-23
TW201613611A (en) 2016-04-16
EP3119794B1 (en) 2017-10-11
EA201692422A1 (ru) 2017-04-28
BR112016025787B1 (pt) 2022-12-13
IL248345A0 (en) 2016-11-30
JP7329025B2 (ja) 2023-08-17
JP2020079255A (ja) 2020-05-28
US20170095498A1 (en) 2017-04-06
KR20220104270A (ko) 2022-07-26
EP3119794A1 (en) 2017-01-25
AU2019204557A1 (en) 2019-07-18
IL276199B (en) 2022-04-01
PL3119794T3 (pl) 2018-04-30
EP3269391A1 (en) 2018-01-17
HK1244437A1 (en) 2018-08-10
CN110882268A (zh) 2020-03-17
MX373942B (es) 2020-07-13
KR20170042501A (ko) 2017-04-19
EA033046B1 (ru) 2019-08-30
NO3119794T3 (enExample) 2018-03-10
TW201945007A (zh) 2019-12-01
TWI674097B (zh) 2019-10-11
US20200397810A1 (en) 2020-12-24
US10117888B2 (en) 2018-11-06
PT3119794T (pt) 2018-01-15
HUE036011T2 (hu) 2018-06-28
CA2944966C (en) 2022-10-25
AU2019204557B2 (en) 2020-08-27
NZ725009A (en) 2021-02-26
CN106470672B (zh) 2019-11-05
SG11201608809RA (en) 2016-11-29
US10786523B2 (en) 2020-09-29

Similar Documents

Publication Publication Date Title
ES2655820T3 (es) Formulación que comprende un profármaco de gemcitabina
JP7648458B2 (ja) ヌクレオシド薬剤のアミド亜リン酸エステル誘導体の製剤
NZ725009B2 (en) Formulation comprising a gemcitabine-prodrug
EA042714B1 (ru) Состав, содержащий пролекарство гемцитабина
HK1227880A1 (en) Formulation comprising a gemcitabine-prodrug
HK1227880B (en) Formulation comprising a gemcitabine-prodrug
NZ743479A (en) Formulations of phosphoramidate derivatives of nucleoside drugs